Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Inclusion Criteria:

• Histology or cytology confirmed as pancreatic ductal adenocarcinoma;
• ECOG 0-1;
• adequate organ function (absolute neutrophil count ≥1.5 x 109/L; platelet count ≥100 x 109/L; creatinine < 1.5 x ULN (upper normal) or calculated creatinine clearance (CRCI) ≥ 60mL/min; albumin ≥ 30g/L; total bilirubin <1.5 x ULN; aspartateaminotransferase (AST) < 2.5 x ULN; alanine aminotransferase (ALT) < 2.5x ULN; INR orPT < 1.5x ULN, and aPTT <1.5x ULN);
• no obvious symptoms of jaundice and ascites;
• no other serious underlying diseases

Exclusion Criteria:

• patients with active brain metastases;
• history of autoimmune diseases, or need to be treated with corticosteroids andimmunosuppressive agents;
• past history of unstable angina, symptomatic congestive heart failure, severearrhythmia, myocardial infarction within 6 months, QT interval prolongation (>450ms);
• other malignant tumors within the last 5 years;
• pregnant or lactating women;
• NRS ≥ 4 points;
• unintentional weight loss ≥ 5% within 1 month before the first dose even if peripheralor central vein nutrition support,